NeuroMetrix Reports Q4 and Full Year 2017 Financial Results

Medical Device Investing

NeuroMetrix (Nasdaq:NURO) reported financial and business highlights for the quarter ended December 31, 2017. As quoted in the update: Q4 2017 revenue of $4.9 million grew 33% from $3.7 million in Q4 2016. Quell contributed $3.7 million and DPNCheck added $0.8 million revenue. Full year 2017 revenue of $17.1 million grew 42% from $12.0 million …

NeuroMetrix (Nasdaq:NURO) reported financial and business highlights for the quarter ended December 31, 2017.
As quoted in the update:

Q4 2017 revenue of $4.9 million grew 33% from $3.7 million in Q4 2016. Quell contributed $3.7 million and DPNCheck added $0.8 million revenue.
Full year 2017 revenue of $17.1 million grew 42% from $12.0 million in 2016. Quell contributed $12.4 million and DPNCheck contributed $3.1 million revenue.
Fourth quarter Quell shipments totaled 26,496 devices and 36,556 electrode reorder packages. This compared with 14,301 devices and 19,993 electrode reorder packages in Q4 2016.

Click here to read the full update.

q4 2016 Medical Device Investing